Ann: Quarterly Update and Appendix 4C, page-28

FDA approval has been a long time coming. First Trials were organised 2020, but put on hold due to Covid and basically all applications on hold till the pandemic emergency was over. It was discussed over and over that The Painchek app was not a priority in aged care when people were dying of C19, pain assessment was bottom of the priority list. Now that things are back to new normal, everybody can again re evaluate the age care sector and bring objective comfort and dignity to those requiring pain management. Trials are underway, FDA and Painchek have had communication of requirements, which I feel is really only a formality as every other country that we have introduced the technology to, have approved it, after trials provide proof of concept.
If the current trend continues as it currently sits now, after 2 years
25% of Australian beds= 50 000 beds
can we expect after 2 years of exposure
25% of UK = 110 000
25% of USA = 250 000
ARR of circa $20 000 000 this without infant app, kids app, disabled app, home care, hospital, pharmacy etc, and additional market penetration in Australia & NZ,
Also next market , Germany, Japan both huge markets.
IMO
This has been our exposure year, with every post a winner, next year will be a transformative year hitting cost neutral, 2025 will see this move into the exponential curve of profit as momentum gathers.
Patience is all that’s required by us holders.
cheers.
DYOR.